Physician profile
Ralph Sulser
NPI 1184631293
$317.05
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $46.15 | 2019 | |
| Amarin Pharma, INC. | $39.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.51 | 2019 | |
| Novo Nordisk INC | $27.13 | 2019 | |
| Abbvie INC. | $25.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.61 | 2019 | |
| Vapotherm INC | $20.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.17 | 2019 | |
| Merck Sharp & Dohme LLC | $12.92 | 2019 | |
| Abbott Laboratories | $12.51 | 2019 | |
| Allergan, INC. | $11.72 | 2019 | |
| Amgen INC. | $10.95 | 2019 | |
| Pfizer INC. | $10.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Sulser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.